The Critical Path For Alzheimer’s Disease (CPAD) is a de-identified database directed by Critical Path Institute. The database collects patient-level data from 12811 patients across 36 clinical trials of AD and MCI. It contains demographic information, APOE4 genotype, concomitant medications, and cognitive scales, such as MMSE and ADAS-Cog. It also provides limited treatment-arm data and limited AD biomarker data including biofluid, tau or amyloid positron emission tomography (PET), EEG data. All data in this database have been remapped to the CDISC SDTM v3.1.2 data standard.
This database is open to CPAD members, as well as to external qualified researchers who submit, and are approved for, a request for access.
View Resource